Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin
- Conditions
- T2DM (Type 2 Diabetes Mellitus)
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- HighTide Biopharma Pty Ltd
- Target Recruit Count
- 418
- Registration Number
- NCT06415773
- Locations
- 🇨🇳
Beijing Pinggu Hospital, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, China
🇨🇳Binzhou Medical University Hospital, Binzhou, China
A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- HighTide Biopharma Pty Ltd
- Target Recruit Count
- 113
- Registration Number
- NCT06411275
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳The Second Hospital of Jilin University, Chang chun, China
🇨🇳The First People's Hospital of Changde City, Changde, China
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- HighTide Biopharma Pty Ltd
- Target Recruit Count
- 551
- Registration Number
- NCT06353347
- Locations
- 🇨🇳
Baogang Hospital of Inner Mongolia, Baotou, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, China
🇨🇳Beijing Luhe Hospital Capital Medical University, Beijing, China
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
- Conditions
- T2DM (Type 2 Diabetes Mellitus)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- HighTide Biopharma Pty Ltd
- Target Recruit Count
- 408
- Registration Number
- NCT06350890
- Locations
- 🇨🇳
Xuancheng People's Hospital, Xuancheng, Anhui, China
🇨🇳Beijing Pinggu Hospital, Beijing, Beijing, China
🇨🇳Fuwai Hospital, CAMS & PUMC, Beijing, Beijing, China
HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes
- Conditions
- Nonalcoholic Steatohepatitis (NASH)Type 2 Diabetes
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- HighTide Biopharma Pty Ltd
- Target Recruit Count
- 218
- Registration Number
- NCT05623189
- Locations
- 🇵🇷
FDI Clinical Research, San Juan, Puerto Rico
🇺🇸The Institute for Liver Health (Arizona Liver Health), Chandler, Arizona, United States
🇺🇸Arizona Liver Health - Glendae, Peoria, Arizona, United States
- Prev
- 1
- 2
- 3
- Next